Glucosamine Linked to Higher Dementia Progression and Mortality Risk
- To determine whether the popular joint supplement influences neurodegenerative conditions, researchers utilized artificial intelligence to analyze deidentified UF Health records collected between 2012 and 2024.
- After controlling for age, sex, and demographic variables, the analysis revealed that glucosamine use correlated with a 25 percent increased risk of progressing from mild cognitive impairment to...
- Study authors emphasized that electronic health record observations demonstrate an association rather than direct causation, noting that unmeasured differences between supplement users and non-users could influence the outcomes.
University of Florida Analysis Tracks Records From 2012 to 2024
To determine whether the popular joint supplement influences neurodegenerative conditions, researchers utilized artificial intelligence to analyze deidentified UF Health records collected between 2012 and 2024. The study focused specifically on patients diagnosed with Alzheimer’s disease and related dementias or mild cognitive impairment, a condition defined by measurable memory or thinking problems that exceed normal aging but do not yet prevent independent daily living. Across both patient groups, 8 percent reported using glucosamine, encompassing 1,896 individuals with dementia and 2,750 people with mild cognitive impairment.
After controlling for age, sex, and demographic variables, the analysis revealed that glucosamine use correlated with a 25 percent increased risk of progressing from mild cognitive impairment to full dementia. Among patients who already had an established diagnosis of Alzheimer’s disease or related dementias, glucosamine use was additionally associated with a 25 percent higher mortality risk over a defined period. Researchers did not observe that mortality increase within the mild cognitive impairment cohort, indicating that the supplement may exert a stronger biological effect once neurodegeneration is already advanced.
Investigating the Biological Mechanism Behind the Association
Study authors emphasized that electronic health record observations demonstrate an association rather than direct causation, noting that unmeasured differences between supplement users and non-users could influence the outcomes. The electronic health record data are very provocative,
said Matt Gentry, chair of the University of Florida Department of Biochemistry and Molecular Biology and a co-author of the study, noting that while the findings do not prove causality, they raise a clinical question requiring intensive further study.
To explore potential biological explanations, the team conducted experiments on human brain tissue and mouse models of Alzheimer’s disease using a specialized spatial technology developed in the laboratory of senior author Ramon Sun. This technique mapped thousands of molecules generated during cellular breakdown to uncover hidden metabolic pathways. The investigation pointed toward a pathway involving the attachment of sugar structures to proteins—a standard cellular process that appears to become abnormally overactive in Alzheimer’s disease.
Clinical Implications for Millions Living With Dementia
With approximately 7 million people in the United States living with Alzheimer’s disease and millions more affected by related conditions such as Lewy body or frontotemporal dementia, researchers stress the urgency of understanding common environmental exposures that could alter disease trajectories. Ramon Sun, director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation at the McKnight Brain Institute, noted that many patients actively take over-the-counter products that might unintentionally worsen disease progression.
The authors suggest that identifying altered metabolic pathways could eventually yield new therapeutic targets that complement traditional treatments focused strictly on amyloid-beta plaques and tau tangles. However, because the current findings rely primarily on retrospective data and laboratory models, the results remain preliminary and must be rigorously tested in human clinical trials before definitive medical recommendations can be established.